Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company s Share Capital
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ISIN code: FR0012616852
24 429 165
(1) The total number of gross (or theoretical ) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
(2) The total number of net (or exercisable at a Shareholders Meeting ) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the recommendation made by the AMF on 17 July 2007.
(1)
Regulatory News:
ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients.
In the context of the Covid-19 pandemic and in order to protect all shareholders, the Board of Directors has decided to hold the Combined General Meeting of June 11, 2021 at 9:00 am at the headquarters, in camera, without the physical presence of the shareholders and other persons entitled to attend.
On June 1
st, 2021, the Chief Executive Officer, upon delegation of the Board of Directors, proceeded, in accordance with the provisions of article 8 of the extended and modified decree n° 2020-418 of April 10, 2020, to appoint Mr. Luc Demarre and Mr. Cyrille Tupin as scrutineers for the next Combined General Meeting of Shareholders of ABIONYX PHARMA. In accordance with the regulations, they are among the ten shareholders with the highest number of voting rights of which the company is aware at
ABIONYX Pharma: Monthly statement of total voting rights and shares forming the company s share capital
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ISIN code: FR0012616852
24 353 083
(1) The total number of gross (or theoretical ) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
(2) The total number of net (or exercisable at a Shareholders Meeting ) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the recommendation made by the AMF on 17 July 2007.
ABIONYX Pharma: ABIONYX Announces Positive Clinical Results From CER-001 in the LCAT Deficiency Disease Published in the Annals of Internal Medicine
Confirmation of the breakthrough therapy status of CER-001 in kidney and ophthalmic diseases
Systemic mechanism of action of CER-001
ABIONYX Pharma (
FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to innovative therapies for patients, today announces positive clinical results from CER-001 in the LCAT (lecithin-cholesterol acyltransferase) deficiency disease published in the
Annals of Internal Medicine
The patient with inherited mutations in the lecithin-cholesterol acyltransferase (LCAT) gene developed glomerulopathy and corneal lipid deposits and displayed very low circulating levels of high-density lipoprotein (HDL) and apoA-I. The patient was treated with CER-001, an apoA-I-containing HDL mimetic, to help in preventing rapidly progressive kidney failure.